ReviewFrontiers in cell and developmental biology2026
From pathophysiology to therapy: molecular mechanisms of stem cell and extracellular vesicle-mediated repair in diabetic peripheral neuropathy.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic peripheral neuropathy (DPN) is a prevalent diabetic complication with limited effective treatments. While stem cell-based therapies show promise, their efficacy is attributed to paracrine activity, particularly extracellular vesicles (EVs). This review examines the molecular pathology of DPN, focusing on metabolic dysregulation, neuroinflammation, and neurovascular dysfunction. The mechanisms by which stem cells and their EVs counteract these processes are elucidated, including activating antioxidant pathways (NRF2/HO-1), reprogramming immune signaling (M1 to M2 polarization), and promoting neurovascular regeneration (PI3K/Akt, MAPK). Innovations in EV engineering aimed at enhancing their molecular cargo and targeting specificity are critically assessed. Furthermore, the translational challenges for these EV-based therapies are addressed, focusing on the need for standardized production to ensure molecular consistency. It is concluded that EV-based cell-free therapy represents a novel regenerative strategy for DPN, operating through multi-targeted molecular mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.